NASDAQ: NGNE · Life Sciences · 2 alerts · CIK 1404644
Share price
$23.30Close, Nov 16
Market cap
$482M
Shares outstanding
20.7MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Neurogene Inc. filings on SEC EDGAR ↗
Neurogene Inc. reported a net loss of $94.4 million for the nine months ended September 30, 2026, driven by increased R&D expenses for its Rett syndrome clinical programs. The company significantly strengthened its liquidity through a July 2026 public offering and at-the-market sales, ending the period with $362.7 million in total current assets.
Neurogene Inc. reported third quarter 2026 financial results and provided a clinical update on its NGN-401 gene therapy program for Rett syndrome. The company expects topline data from its Embolden registrational trial in the second half of 2027 and confirmed its cash runway extends into the first quarter of 2029.
Term
Q3 2026
“During the third quarter, we continued to execute across all aspects of our NGN-401 program as we advance toward potential commercialization. With topline data from the Embolden registrational trial expected in the second half of 2027, we are progressing key BLA and commercial-readiness activities, including PPQ runs that we believe remain on track for completion this year.”
Rachel McMinn, Ph.D., Founder and Chief Executive Officer